Company news
Beam Therapeutics Inc. news in 2021
Beam Therapeutics Inc.'s news releases, calls and decks from 2021, newest first.
Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH
December 11, 2021
Beam Therapeutics Reports Preclinical Data Highlighting Multiplex Base Editing Approach to Create Anti-CD5 CAR T-cell Investigational Therapies for T-Cell Malignancies
November 11, 2021
Beam Therapeutics to Participate in the Jefferies 2021 Virtual London Healthcare Conference
November 10, 2021
Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results
November 7, 2021
Beam Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to its Board of Directors
November 7, 2021
Beam Therapeutics Announces Upcoming Preclinical Data Presentations at the American Society of Hematology Annual Meeting
November 3, 2021
Beam Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit
October 19, 2021
Beam Therapeutics Announces Preclinical Data Highlighting Base Editing Approach to Correct a Glycogen Storage Disease Type Ia Disease-Causing Mutation
October 18, 2021
Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeting CD5 at 2021 SITC Annual Meeting
September 30, 2021
Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
September 27, 2021
Beam Therapeutics Announces Preclinical Data Highlighting Potential of Base Editors to Target Disease Drivers of Chronic Hepatitis B Infection
September 26, 2021
Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues
September 22, 2021
Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
September 7, 2021
Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results
August 9, 2021
Beam Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
August 2, 2021
Beam Therapeutics to Participate in the 2021 William Blair Biotech Focus Conference
July 7, 2021
Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases
June 29, 2021
Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference
May 24, 2021
Beam Therapeutics Presents LNP Formulation Data at ASGCT and Reports First Quarter 2021 Financial Results
May 10, 2021
Beam Therapeutics Announces Oral and Poster Presentations at 24th American Society of Gene and Cell Therapy Annual Meeting
April 26, 2021
Beam Therapeutics Publishes Data Highlighting Ability to Rationally Design Base Editors for Precise Editing
April 19, 2021
Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer
March 14, 2021
Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results
March 14, 2021
Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare Conference
March 3, 2021
Beam Therapeutics Announces Acquisition of Guide Therapeutics
February 22, 2021
Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors
January 18, 2021
Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors
January 10, 2021
Beam Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
Decks in 2021
- Investor Presentation (January 2021)
Investor deck · 34 slides · Jan 12, 2021